Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.

Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
复制标题

DOI:
10.1016/j.nbd.2022.105768
复制
发表时间:
2022-08
影响因子:
6.1
通讯作者:
Moore, Darren J.
Moore, Darren J.
中科院分区:
医学1区
文献类型:
--
作者:
Williams, Erin T.;Chen, Xi;Otero, P. Anthony;Moore, Darren J.

文献摘要

参考文献

相似文献

内溶酶体通路的紊乱在帕金森病(Parkinson's disease,PD)和阿尔茨海默病(Alzheimer's disease,AD)等神经退行性疾病的发病机制中起重要作用。具体而言,VPS35和逆转录聚合物复合物在内溶酶体系统中起重要作用,并与这些疾病的病理生理学有关。已知VPS35中的单个错义突变Asp620Asn(D620N)可导致晚发型常染色体显性遗传家族性PD。在这篇综述中,我们重点关注PD连锁D620N突变在引起retromer功能障碍中的新作用,并剖析其在神经退行性变中的意义。此外,我们将讨论VPS35和retromer如何与AD、肌萎缩侧索硬化和原发性tau蛋白病相关。有趣的是,在死后脑组织中观察到VPS35和其他逆转录酶组分的水平降低,表明逆转录酶在这些疾病的病理生理学中的作用。这篇综述将提供一个全面的潜水VPS35功能障碍的神经退行性疾病的机制。此外,我们将突出该领域的突出问题,并将retromer作为神经退行性疾病的治疗靶点。
Perturbations of the endolysosomal pathway have been suggested to play an important role in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). Specifically, VPS35 and the retromer complex play an important role in the endolysosomal system and are implicated in the pathophysiology of these diseases. A single missense mutation in VPS35, Asp620Asn (D620N), is known to cause late-onset, autosomal dominant familial PD. In this review, we focus on the emerging role of the PD-linked D620N mutation in causing retromer dysfunction and dissect its implications in neurodegeneration. Additionally, we will discuss how VPS35 and the retromer are linked to AD, amyotrophic lateral sclerosis, and primary tauopathies. Interestingly, reduced levels of VPS35 and other retromer components have been observed in post-mortem brain tissue, suggesting a role for the retromer in the pathophysiology of these diseases. This review will provide a comprehensive dive into the mechanisms of VPS35 dysfunction in neurodegenerative diseases. Furthermore, we will highlight outstanding questions in the field and the retromer as a therapeutic target for neurodegenerative disease at large.
DOI: 10.1038/s41531-018-0063-3
发表时间: 2018
期刊: NPJ Parkinson's disease
影响因子: --
作者:
Cataldi S;Follett J;Fox JD;Tatarnikov I;Kadgien C;Gustavsson EK;Khinda J;Milnerwood AJ;Farrer MJ
通讯作者: Farrer MJ
DOI: 10.1016/j.cub.2010.05.066
发表时间: 2010-07-27
期刊: CURRENT BIOLOGY
影响因子: 9.2
作者:
Braschi, Emelie;Goyon, Vanessa;McBride, Heidi M.
通讯作者: McBride, Heidi M.
帕金森氏病的遗传结构。
DOI: 10.1016/s1474-4422(19)30287-x
发表时间: 2020-02
期刊: The Lancet. Neurology
影响因子: --
作者:
Blauwendraat C;Nalls MA;Singleton AB
通讯作者: Singleton AB
DOI: 10.1007/s12035-020-01926-1
发表时间: 2020-07
影响因子: 5.1
作者:
Compagnoni, Giacomo Monzio;Di Fonzo, Alessio;Corti, Stefania;Comi, Giacomo P.;Bresolin, Nereo;Masliah, Eliezer
通讯作者: Masliah, Eliezer
健康衰老和疾病中的自噬。
DOI: 10.1038/s43587-021-00098-4
发表时间: 2021-08
期刊: Nature aging
影响因子: --
作者:
Aman Y;Schmauck-Medina T;Hansen M;Morimoto RI;Simon AK;Bjedov I;Palikaras K;Simonsen A;Johansen T;Tavernarakis N;Rubinsztein DC;Partridge L;Kroemer G;Labbadia J;Fang EF
通讯作者: Fang EF